Advice

following a full submission assessed under the end of life process:

nivolumab (Opdivo®) is accepted for restricted use within NHS Scotland.

Indication under review: treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

SMC restriction: treatment with nivolumab is subject to a two-year clinical stopping rule. 

Nivolumab, compared with a standard, second-line chemotherapy, significantly increased overall survival in patients with locally advanced or metastatic non-squamous NSCLC who had received previous therapy including platinum-based doublet chemotherapy.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of nivolumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Download detailed advice238KB (PDF)

Download

Medicine details

Medicine name:
nivolumab (Opdivo)
SMC ID:
1180/16
Indication:
treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Restricted
Date advice published:
10 October 2016